BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/15/2022 11:41:26 AM | Browse: 523 | Download: 1322
 |
Received |
|
2022-07-20 06:46 |
|
Peer-Review Started |
|
2022-07-20 06:48 |
|
First Decision by Editorial Office Director |
|
2022-09-04 06:56 |
|
Return for Revision |
|
2022-09-04 06:56 |
|
Revised |
|
2022-09-20 04:46 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-10-24 03:56 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-10-28 18:18 |
|
Articles in Press |
|
2022-10-28 18:18 |
|
Edit the Manuscript by Language Editor |
|
2022-10-20 22:38 |
|
Typeset the Manuscript |
|
2022-11-07 01:53 |
|
Publish the Manuscript Online |
|
2022-12-15 11:41 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Comparison of gliclazide vs linagliptin on hypoglycemia and cardiovascular events in type 2 diabetes mellitus: A systematic review
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Viswanathan Mohan, Subhash Wangnoo, Sambit Das, Rajnish Dhediya and Kumar Gaurav |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Rajnish Dhediya, MBBS, MD, N/A, N/A, Medical Affairs, Dr. Reddy’s Laboratories Ltd, 7-1-27 Ameerpet, Hyderabad 500016, India. rajnishd@drreddys.com |
| Key Words |
Linagliptin; Gliclazide; Hypoglycemia; Major cardiovascular adverse events; Type 2 diabetes |
| Core Tip |
This systematic review showed the lack of high-quality evidence and head-to head trials comparing the cardiovascular safety and hypoglycemia risk of gliclazide (a sulfonylurea) vs linagliptin (dipeptidyl peptidase-4 inhibitor) in adults with type 2 diabetes and no cardiovascular disease. While dipeptidyl peptidase-4 inhibitors have been proven to be cardiovascular neutral, sulfonylureas like gliclazide are commonly prescribed and recommended glucose-lowering drugs in low resource settings. Hence, it is important to establish the cardiovascular safety and hypoglycemia risk of gliclazide vs linagliptin to highlight that gliclazide may be a cost-effective yet safe treatment option for patients with type 2 diabetes. |
| Publish Date |
2022-12-15 11:41 |
| Citation |
Mohan V, Wangnoo S, Das S, Dhediya R, Gaurav K. Comparison of gliclazide vs linagliptin on hypoglycemia and cardiovascular events in type 2 diabetes mellitus: A systematic review. World J Diabetes 2022; 13(12): 1168-1183 |
| URL |
https://www.wjgnet.com/1948-9358/full/v13/i12/1168.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v13.i12.1168 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
